Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

CBER Director Touts PDUFA Progress, Therapeutic Firsts in Fiscal 2017

  • Post author:Sam
  • Post published:January 5, 2018
  • Post category:Drug Industry Daily

The Center for Biologics Research and Evaluation met or exceeded its PDUFA goals in fiscal 2017, according to CBER Director Peter Marks. Source: Drug Industry Daily

Continue ReadingCBER Director Touts PDUFA Progress, Therapeutic Firsts in Fiscal 2017

After Kickback Scandal Ends Charity’s Free Drug Program, OIG Urges PhRMA to Step In

  • Post author:Sam
  • Post published:January 5, 2018
  • Post category:Drug Industry Daily

The Department of Health and Human Services’ Office of Inspector General sent a letter to PhRMA seeking help in contributing to drug co-payments after a nonprofit ended its financial grants…

Continue ReadingAfter Kickback Scandal Ends Charity’s Free Drug Program, OIG Urges PhRMA to Step In

Report Flags Price Transparency As a Key Issue for 2018

  • Post author:Sam
  • Post published:January 5, 2018
  • Post category:Drug Industry Daily

Drug pricing will be a key healthcare issue for 2018, with state pricing and transparency laws pushing pharma and life science companies to reconsider strategies and business models, according to…

Continue ReadingReport Flags Price Transparency As a Key Issue for 2018

Kala Pharma Sinks on Mixed Data From Two Phase III Dry Eye Disease Studies

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

Kala Pharma released mostly positive topline results from two Phase III clinical trials for KPI-121 in patients with dry eye disease. Source: BioSpace

Continue ReadingKala Pharma Sinks on Mixed Data From Two Phase III Dry Eye Disease Studies

What You Need to Know About Relay Therapeutics

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

Based in Cambridge, MA and founded in February 2016, Relay Therapeutics focuses on developing therapeutics based on protein motion. Source: BioSpace

Continue ReadingWhat You Need to Know About Relay Therapeutics

Busy Takeda Takes Out Tigenix in $630M Deal

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced. Source: BioSpace

Continue ReadingBusy Takeda Takes Out Tigenix in $630M Deal

Pernix Takes the Ax to 22% of Workforce in Reorg

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

The company will undergo a reorganization that includes the termination of a number of sales representatives. Source: BioSpace

Continue ReadingPernix Takes the Ax to 22% of Workforce in Reorg

Longtime CEO at Bay Area's OncoMed Steps Down

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

Board of Directors has initiated search to identify successor. Source: BioSpace

Continue ReadingLongtime CEO at Bay Area's OncoMed Steps Down

KBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

The financing was co-led by Advantech Capital and SDIC Venture Capital. Source: BioSpace

Continue ReadingKBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly

3 Biotechs That Could Outperform in 2018

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

A look at why investors should stock up on Amgen, Celldex Therapeutics, and Novavax soon. Source: BioSpace

Continue Reading3 Biotechs That Could Outperform in 2018
  • Go to the previous page
  • 1
  • …
  • 207
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.